Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Go back to Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals| ARROWHEAD RESEARCH (NASDAQ: ARWR) | Delayed: 87.11 -0.36 (0.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $87.47 | 52 Week High | $8.22 | |||
| Open | $87.90 | 52 Week Low | $3.07 | |||
| Day High | $88.46 | P/E | N/A | |||
| Day Low | $85.94 | EPS | $-1.30 | |||
| Volume | 1,090,198 | |||||
| (NASDAQ: MDGL) | Delayed: 516.74 -2.35 (0.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $519.09 | 52 Week High | $18.24 | |||
| Open | $520.09 | 52 Week Low | $6.60 | |||
| Day High | $530.67 | P/E | N/A | |||
| Day Low | $514.91 | EPS | $0.00 | |||
| Volume | 179,832 | |||||
